MSN Labs Gets SEC Nod for Roflumilast as Starting Dose in COPD Therapy
New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has recommended the grant of permission to manufacture and market Roflumilast Tablets 250 mcg by MSN Laboratories Pvt. Ltd., indicated as a starting dose in the already approved indication for Chronic Obstructive Pulmonary Disease (COPD). The submission, registered under file […]
